Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein.

Staneková Z, Király J, Stropkovská A, Mikušková T, Mucha V, Kostolanský F, Varečková E.

Acta Virol. 2011;55(1):61-7.

PMID:
21434706
2.

Influenza virus-like particles containing M2 induce broadly cross protective immunity.

Song JM, Wang BZ, Park KM, Van Rooijen N, Quan FS, Kim MC, Jin HT, Pekosz A, Compans RW, Kang SM.

PLoS One. 2011 Jan 18;6(1):e14538. doi: 10.1371/journal.pone.0014538.

3.

Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus.

Hashem AM, Van Domselaar G, Li C, Wang J, She YM, Cyr TD, Sui J, He R, Marasco WA, Li X.

Biochem Biophys Res Commun. 2010 Dec 10;403(2):247-51. doi: 10.1016/j.bbrc.2010.11.030. Epub 2010 Nov 13.

PMID:
21078301
4.

Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes.

Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, Wilson IA, García-Sastre A, Moran TM, Palese P.

Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18979-84. doi: 10.1073/pnas.1013387107. Epub 2010 Oct 18.

5.

Influenza virus vaccine based on the conserved hemagglutinin stalk domain.

Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, García-Sastre A, Palese P.

MBio. 2010 May 18;1(1). pii: e00018-10. doi: 10.1128/mBio.00018-10.

6.

Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge.

Bommakanti G, Citron MP, Hepler RW, Callahan C, Heidecker GJ, Najar TA, Lu X, Joyce JG, Shiver JW, Casimiro DR, ter Meulen J, Liang X, Varadarajan R.

Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13701-6. doi: 10.1073/pnas.1007465107. Epub 2010 Jul 6.

7.

Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization.

Quan FS, Kim YC, Vunnava A, Yoo DG, Song JM, Prausnitz MR, Compans RW, Kang SM.

J Virol. 2010 Aug;84(15):7760-9. doi: 10.1128/JVI.01849-09. Epub 2010 May 19.

8.

Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins.

Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, Palese P.

PLoS Pathog. 2010 Feb 26;6(2):e1000796. doi: 10.1371/journal.ppat.1000796.

9.

Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity.

Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR.

J Control Release. 2010 Mar 3;142(2):187-95. doi: 10.1016/j.jconrel.2009.10.013. Epub 2009 Oct 17.

10.

Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin.

Quan FS, Kim YC, Yoo DG, Compans RW, Prausnitz MR, Kang SM.

PLoS One. 2009 Sep 25;4(9):e7152. doi: 10.1371/journal.pone.0007152.

11.

Antibody recognition of a highly conserved influenza virus epitope.

Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA.

Science. 2009 Apr 10;324(5924):246-51. doi: 10.1126/science.1171491. Epub 2009 Feb 26.

12.

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses.

Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA.

Nat Struct Mol Biol. 2009 Mar;16(3):265-73. doi: 10.1038/nsmb.1566. Epub 2009 Feb 22.

13.

Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection.

Prabhu N, Prabakaran M, Ho HT, Velumani S, Qiang J, Goutama M, Kwang J.

J Virol. 2009 Mar;83(6):2553-62. doi: 10.1128/JVI.02165-08. Epub 2008 Dec 24.

14.

Induction of heterosubtypic immunity to influenza virus by intranasal immunization.

Quan FS, Compans RW, Nguyen HH, Kang SM.

J Virol. 2008 Feb;82(3):1350-9. Epub 2007 Nov 21.

15.

Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.

Quan FS, Huang C, Compans RW, Kang SM.

J Virol. 2007 Apr;81(7):3514-24. Epub 2007 Jan 24.

16.

Role of hemagglutinin cleavage for the pathogenicity of influenza virus.

Steinhauer DA.

Virology. 1999 May 25;258(1):1-20. Review.

17.

An antibody which binds to the membrane-proximal end of influenza virus haemagglutinin (H3 subtype) inhibits the low-pH-induced conformational change and cell-cell fusion but does not neutralize virus.

Vanlandschoot P, Beirnaert E, Barrère B, Calder L, Millar B, Wharton S, Jou WM, Fiers W.

J Gen Virol. 1998 Jul;79 ( Pt 7):1781-91.

PMID:
9680143
18.

Membrane fusion by influenza hemagglutinin.

Skehel JJ, Bizebard T, Bullough PA, Hughson FM, Knossow M, Steinhauer DA, Wharton SA, Wiley DC.

Cold Spring Harb Symp Quant Biol. 1995;60:573-80. Review. No abstract available.

PMID:
8824430
19.

Structure of influenza haemagglutinin at the pH of membrane fusion.

Bullough PA, Hughson FM, Skehel JJ, Wiley DC.

Nature. 1994 Sep 1;371(6492):37-43.

PMID:
8072525
20.

Electron microscopy of antibody complexes of influenza virus haemagglutinin in the fusion pH conformation.

Wharton SA, Calder LJ, Ruigrok RW, Skehel JJ, Steinhauer DA, Wiley DC.

EMBO J. 1995 Jan 16;14(2):240-6.

Supplemental Content

Support Center